{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:21:46Z","timestamp":1784719306159,"version":"3.55.0"},"reference-count":109,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"4","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can Pharm J"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Canada has historically been among the world leaders in hypertension care, but hypertension treatment and control rates have regressed in recent years. This guideline is intended to provide pragmatic primary care-focused recommendations to improve hypertension management in adults at the population level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We employed Grading of Recommendations Assessment, Development and Evaluation and ADAPTE frameworks in accordance with Appraisal of Guidelines for Research and Evaluation (AGREE II) quality and reporting standards to develop recommendations on managing hypertension for adults aged 18\u2009years and older. We used the HEARTS framework\u2014a model of care developed by the World Health Organization to improve hypertension control and reduce cardiovascular burden\u2014to integrate these recommendations into streamlined, pragmatic, and evidence-based algorithms. The guideline committee predominantly comprised primary care providers and also included patient, methodology, and hypertension specialist representatives. Our process for managing competing interests adhered to Guidelines International Network principles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recommendations:<\/jats:title>\n                    <jats:p>The 9 recommendations for managing hypertension in adults are grouped under the categories of diagnosis and treatment. Diagnostic recommendations include a standardized approach to measuring blood pressure (BP) and confirming hypertension, as well as providing a uniform definition for hypertension of BP \u2265130\/80\u2009mmHg. Treatment recommendations include targeting a systolic BP &lt;130\u2009mmHg, implementing healthy lifestyle changes, and providing stepwise guidance on optimal medication choices for patients requiring pharmacotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation:<\/jats:title>\n                    <jats:p>Our aim is to enhance the standard of hypertension care in the Canadian primary care setting. Accurate diagnosis and optimal treatment of hypertension can reduce adverse cardiovascular events and risk of death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17151635251343907","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:12:05Z","timestamp":1748326325000},"page":"188-205","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care"],"prefix":"10.3138","volume":"158","author":[{"given":"R\u00e9mi","family":"Goupil","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross T.","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"EPICORE, Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Santesso","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Terenzi","sequence":"additional","affiliation":[{"name":"Langstaff Medical Centre, Woodbridge, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Habert","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montr\u00e9al, QC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie C.","family":"Gysel","sequence":"additional","affiliation":[{"name":"Apothecare Pharmacy, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Bruneau","sequence":"additional","affiliation":[{"name":"Faculty of Nursing, Memorial University of Newfoundland, St. John\u2019s, NL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, and Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman R.C.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute, Department of Medicine, University of Calgary, Calgary, AB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto L.","family":"Schiffrin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montr\u00e9al, QC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Hundemer","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Ottawa"},{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206916"},{"key":"e_1_3_3_3_2","first-page":"14","article-title":"Blood pressure and hypertension","volume":"30","author":"DeGuire J","year":"2019","unstructured":"DeGuire J, Clarke J, Rouleau K, Roy J, Bushnik T. Blood pressure and hypertension. Health Rep 2019;30:14-21.","journal-title":"Health Rep"},{"key":"e_1_3_3_4_2","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398:957-80.","journal-title":"Lancet"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.02.092"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2024.05.012"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.210140"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2024.10.020"},{"key":"e_1_3_3_9_2","volume-title":"HEARTS technical package for cardiovascular disease management in primary health care: risk based CVD management","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. HEARTS technical package for cardiovascular disease management in primary health care: risk based CVD management. Geneva (Switzerland): World Health Organization; 2020."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.108769"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12803"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.12.004"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.02.021"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.03.007"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000087"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10237"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24464"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2023.10.001"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001197"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.3264"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.5213"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2022.12.015"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12079"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6551"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.5028"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.0315"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111437"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01028-6"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412006"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.02.086"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00733-X"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01275"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2019.08.006"},{"key":"e_1_3_3_36_2","article-title":"Screening for hypertension in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"325","author":"Guirguis-Blake JM","year":"2021","unstructured":"Guirguis-Blake JM, Evans CV, Webber EM, Coppola EL, Perdue LA, Weyrich MS. Screening for hypertension in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2021;325:1657-69.","journal-title":"JAMA"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60685-1"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-013-0403-y"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.23597"},{"key":"e_1_3_3_40_2","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021;397:1625-36.","journal-title":"Lancet"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61340-4"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60852-1"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.6192"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901281"},{"key":"e_1_3_3_45_2","article-title":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis","volume":"398","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021;398:1053-64.","journal-title":"Lancet"},{"key":"e_1_3_3_46_2","article-title":"Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials","volume":"368","author":"Huang L","year":"2020","unstructured":"Huang L, Trieu K, Yoshimura S, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ 2020;368:m315.","journal-title":"BMJ"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105675"},{"key":"e_1_3_3_48_2","first-page":"1","volume-title":"Guideline: sodium intake for adults and children","author":"World Health Organization","unstructured":"World Health Organization. Guideline: sodium intake for adults and children. Geneva (Switzerland): World Health Organization; 2012:1-56."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.1991.10718167"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31376-X"},{"key":"e_1_3_3_51_2","article-title":"Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses","volume":"346","author":"Aburto NJ","year":"2013","unstructured":"Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013;346:f1378.","journal-title":"BMJ"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311889"},{"key":"e_1_3_3_53_2","first-page":"1","volume-title":"Guideline: potassium intake for adults and children","author":"World Health Organization","unstructured":"World Health Organization. Guideline: potassium intake for adults and children. Geneva (Switzerland): World Health Organization; 2012:1-52."},{"key":"e_1_3_3_54_2","article-title":"Long-term effects of weight-reducing diets in people with hypertension","volume":"2","author":"Semlitsch T","year":"2021","unstructured":"Semlitsch T, Krenn C, Jeitler K, Berghold A, Horvath K, Siebenhofer A. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2021;2:CD008274.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e3280128bbb"},{"key":"e_1_3_3_57_2","first-page":"1","volume-title":"WHO guidelines on physical activity and sedentary behaviour","author":"World Health Organization","unstructured":"World Health Organization. WHO guidelines on physical activity and sedentary behaviour. Geneva (Switzerland): World Health Organization (WHO); 2020:1-104."},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30003-8"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2020.03.018"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.37.2.187"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyab087"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0773"},{"key":"e_1_3_3_63_2","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos C","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 2017;35:2150-60.","journal-title":"J Hypertens"},{"key":"e_1_3_3_64_2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino RB","year":"2008","unstructured":"D\u2019Agostino RBSr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.","journal-title":"Circulation"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"e_1_3_3_66_2","article-title":"Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control","volume":"137","author":"Beddhu S","year":"2018","unstructured":"Beddhu S, Chertow GM, Cheung AK, et al. Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation 2018;137:134-43.","journal-title":"Circulation"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1427"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01225-8"},{"key":"e_1_3_3_69_2","article-title":"Beta-blockers for hypertension","volume":"1","author":"Wiysonge CS","year":"2017","unstructured":"Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2017;1:CD002003.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.09.001"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.01.017"},{"key":"e_1_3_3_72_2","first-page":"1","volume-title":"Guideline for the pharmacological treatment of hypertension in adults","author":"World Health Organization","unstructured":"World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva (Switzerland): World Health Organization; 2021:1-61."},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001456"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212270"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.096156"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15781"},{"key":"e_1_3_3_77_2","article-title":"Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Salam A","year":"2019","unstructured":"Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019;37:1768-74.","journal-title":"J Hypertens"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.139816"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11308"},{"key":"e_1_3_3_80_2","article-title":"Reducing costs and improving hypertension management","volume":"16","author":"Stankus V","year":"2009","unstructured":"Stankus V, Hemmelgarn B, Campbell NR, Chen G, McAlister FA, Tsuyuki RT. Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009;16:e151-5.","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006986"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.194167"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303154"},{"key":"e_1_3_3_84_2","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","unstructured":"ONTARGET Investigators;Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.18080"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.025"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.10359"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30071-8"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110459"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105835"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4873"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.052"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0065"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzi108"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090449"},{"key":"e_1_3_3_100_2","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:1269-324.","journal-title":"Hypertension"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1885"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14950"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208391"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213169"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02034-7"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.22314"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067626"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"e_1_3_3_110_2","article-title":"World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","author":"WHO CVD Risk Chart Working Group","year":"2019","unstructured":"WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019;7:e1332-45.","journal-title":"Lancet Glob Health"}],"container-title":["Canadian Pharmacists Journal \/ Revue des Pharmaciens du Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17151635251343907","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17151635251343907","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17151635251343907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:04:57Z","timestamp":1772834697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17151635251343907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/17151635251343907"],"URL":"https:\/\/doi.org\/10.1177\/17151635251343907","relation":{},"ISSN":["1715-1635","1913-701X"],"issn-type":[{"value":"1715-1635","type":"print"},{"value":"1913-701X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}